Ömer COŞKUN, Ertan ALTAYLI, Özgür KORU, Mehmet TANYÜKSEL, Ahmet KARAKAŞ, Can Polat EYİGÜN

Nitazoksanid ile Tedavi Edilen Refrakter Bir Giardiazis Olgusu

Giardia intestinalis epidemik/endemik diyare ve gastrointestinal sistem rahatsızlıklarına neden olur. Bu enfeksiyonların tedavisinde etkinliği gösterilmiş ve tedavide kabul görmüş birçok ilaç bulunmaktadır. Bununla birlikte hastaların bir kısmında uygun tedaviye rağmen kişisel tedavi başarısızlıkları bildirilmiştir. Nitazoksanid'in, G. intestinalis dâhil geniş bir spektrumda parazitlere etkili olduğu bildirilmiştir. Bu olgu sunumunda ilaca dirençli bir G. intestinalis enfeksiyonunda nitazoksanid ile tedavisi sunulacaktır.

A Case of Refractory Giardiasis Treated with Nitazoxsanide]

Giardia intestinalis is the cause of both epidemic and endemic diarrhea and upset of the gastrointestinal system. There are a number of drugs whose efficacies are well studied and that have been accepted for the treatment of patients with this infection. However, some individuals experience treatment failure, despite having received successive courses of treatment that have been documented to result in a cure for most patients. Nitazoxanide has been reported to be effective against a broad range of parasites, including G. intestinalis. In this case, we present a case of drug resistance G. intestinalis treated with nitazoxanide.

PDF

___

1. Hill DR. Giardia lambia. In: Gerald L. M, Benneth J. E, Dolin R, editors. Mandell, Douglas and Bennett's principles and practice of infectious diseases. Philadelphia, Pennsylvania. Churchill Livingstone; 2005, p. 3198-3205.
2. Abboud P, Lemee V, Gargala G, et al. Successful treatment of metronidazole- and albendazole-resistant giardiasis with nitazoksanide in a patient with acquired immunodeficiency syndrome. Clin Infect Dis. 2001; 32(12): 1792-1794.
3. Rossignol JF, Ayoub A, Ayers MS. Treatment of diarrhea caused by Giardia intestinalis and Entamoeba histolytica or E. dispar: a randomized, double-blind, placebo-controlled study of nitazoksanide. J Infect Dis. 2001; 184(3): 381-384.
4. Ortiz JJ, Ayoub A, Gargala G, Chegne NL, Favennec L. Randomized clinical study of nitazoksanide compared to metronidazole in the treatment of symptomatic giardiasis in children from Northern Peru. Aliment Pharmacol Ther. 2001; 15(9): 1409-1415.
5. Fox LM, Saravolatz LD. Nitazoksanide: a new thiazolide antiparasitic agent. Clin Infect Dis. 2005; 40(8): 1173-1180.
6. Nash TE, Ohl CA, Thomas E, Subramanian G, Keiser P, Moore TA. Treatment of patients with refractory giardiasis. Clin Infect Dis. 2001; 33(1): 22-28.
7. Khaw M, Panosian CB. Human antiprotozoal therapy: past, present, and future. Clin Microbiol Rev. 1995; 8(3): 427-439.
8. Upcroft P, Upcroft JA. Drug targets and mechanisms of resistance in the anaerobic protozoa. Clin Microbiol Rev. 2001; 14(1): 150- 164.
9. Tejman-Yarden N, Eckmann L. New approaches to the treatment of giardiasis. Curr Opin Infect Dis. 2011; 24(5): 451-456.
10. Bailey JM, Erramouspe J. Nitazoksanide treatment for giardiasis and cryptosporidiosis in children. Ann Pharmacother. 2004; 38(4): 634- 640.
11. Davila-Gutierrez CE, Vasquez C, TrujilloHernandez B, Huerta M. Nitazoksanide compared with quinfamide and mebendazole in the treatment of helminthic infections and intestinal protozoa in children. Am J Trop Med Hyg. 2002; 66(3): 251-254.
12. Rodriguez-Garcia R, Rodriguez-Guzman LM, Cruz del Castillo AH. Effectiveness and safety of mebendazole compared to nitazoksanide in the treatment of Giardia lamblia in children. Rev Gastroenterol Mex. 1999; 64(3): 122-126.
13. Cedillo-Rivera R, Chavez B, Gonzalez-Robles A, Tapia A, Yepez-Mulia L. In vitro effect of nitazoksanide against Entamoeba histolytica, Giardia intestinalis and Trichomonas vaginalis trophozoites. J Eukaryot Microbiol. 2002; 49(3): 201-208.